Nih
Nih funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
PAR-24-301: NICHD Resource Program Grants in Bioinformatics (P41 Clinical Trial Not Allowed)
NIH's NICHD P41 funding opportunity supports mature bioinformatics resources for developmental biology and birth-defects research using animal models through multi-component infrastructure and community-oriented tools, data, and training.
PAR-24-330: Interventions to Reduce Sleep Health Disparities (R01, Clinical Trials Optional)
A NIH Parent R01 announcement supporting non-pharmacological sleep-health interventions, implementation science, and behavioral strategies to reduce sleep-related health disparities among populations with higher burden of poor sleep outcomes.
PAR-25-051: Blueprint Neurotherapeutics Network (BPN) Small-Molecule Drug Discovery (UG3/UH3)
NIH's PAR-25-051 NOFO funds small-molecule neuroscience drug discovery teams in UG3/UH3 phases, with NIH-provided development support through the Blueprint Neurotherapeutics Network.
PAR-25-234: NINDS Ruth L. Kirschstein NRSA Postdoctoral Fellowship (F32, Clinical Trial Not Allowed)
A 2026/2027 NIH Fellowship program for early postdoctoral researchers at NINDS that supports mentored research training in neuroscience and related areas under the F32 mechanism, with no independent clinical trials allowed.
PAR-25-270: NCCIH Natural Product Early Phase Clinical Trial Award (R33)
NIH NOFO for R33 early-phase natural-product clinical trials focused on target-engagement evidence before larger efficacy studies, with a direct-cost cap of $1,050,000 over up to 3 years and strict clinical-trial-only eligibility.
PAR-25-322: Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
NIH’s ESI-focused R01 parent NOFO for projects in a new research direction without preliminary data, with recurring 2026/2027 due dates and up to a 5-year project period.
PAR-25-337: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01, Clinical Trial Optional)
NIH funding opportunity for translational R01 projects that pair academic and industrial partners to move diagnostics, imaging, and care-delivery technologies toward real end-user use in pre-clinical, clinical, and non-clinical settings, with up to $499,000 direct costs per year for up to 5 years.
PAR-25-415: Support for Research Excellence (SuRE-First) Award (R16)
NIH NIGMS SuRE-First grants provide competitive direct research funding to first-time independent faculty at resource-limited U.S. institutions to build research capacity and involve students in biomedical research.
PAR-25-449: Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required)
A NCCIH phased NIH parent R61/R33 NOFO supporting mind-body mechanistic clinical trials with strong preliminary data, explicit feasibility milestones, and continuation criteria, with recurring submission cycles into the 2027 review cycle.
PAR-26-001: Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations that Experience Health Disparities
A recurring NIH parent announcement for NIH-defined clinical trial R01 projects that test and scale SBIRT/P interventions for ATOD use and misuse among adults affected by health disparities.